A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

NCT05035836 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive

Interventions

DRUG: Zanidatamab
DRUG: Letrozole
DRUG: Tamoxifen

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]